Cantor Fitzgerald L. P. Acquires Shares of 22,500 Nuvalent, Inc. $NUVL

Cantor Fitzgerald L. P. bought a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 22,500 shares of the company’s stock, valued at approximately $1,946,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Nuvalent in the third quarter valued at about $38,000. Eastern Bank acquired a new position in Nuvalent during the third quarter worth about $52,000. Persistent Asset Partners Ltd acquired a new position in Nuvalent during the second quarter worth about $88,000. PNC Financial Services Group Inc. grew its stake in Nuvalent by 38.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,632 shares of the company’s stock valued at $125,000 after acquiring an additional 451 shares in the last quarter. Finally, Compass Wealth Management LLC purchased a new stake in Nuvalent during the 3rd quarter valued at about $172,000. Institutional investors and hedge funds own 97.26% of the company’s stock.

Wall Street Analysts Forecast Growth

NUVL has been the topic of a number of research reports. The Goldman Sachs Group raised their target price on shares of Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Guggenheim upped their price target on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. JPMorgan Chase & Co. reduced their price objective on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Finally, HC Wainwright boosted their price objective on Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Fifteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Nuvalent presently has an average rating of “Moderate Buy” and a consensus target price of $138.67.

Nuvalent Price Performance

Shares of NUVL stock opened at $97.93 on Friday. The company has a market capitalization of $7.12 billion, a PE ratio of -16.74 and a beta of 1.32. The firm’s 50-day moving average is $102.97 and its two-hundred day moving average is $96.94. Nuvalent, Inc. has a 12 month low of $55.53 and a 12 month high of $113.01.

Insider Buying and Selling at Nuvalent

In related news, insider Christopher Durant Turner sold 3,181 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $97.16, for a total value of $309,065.96. Following the completion of the transaction, the insider directly owned 55,130 shares in the company, valued at approximately $5,356,430.80. This represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James Richard Porter sold 9,543 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $97.16, for a total value of $927,197.88. Following the sale, the chief executive officer directly owned 278,629 shares of the company’s stock, valued at approximately $27,071,593.64. This trade represents a 3.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 69,379 shares of company stock worth $6,940,982. Insiders own 10.20% of the company’s stock.

Nuvalent Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.